NCT05892614Phase 2Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-04Estimated

Enrollment · participants25Estimated

Source updated2025-05-07Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Interstitial Lung Disease

Treatments or interventions studied

efzofitimod 450 mgDrug
efzofitimod 270 mgDrug
PlaceboDrug

Primary outcomes · main study measures

measure: Absolute change from baseline in forced vital capacity (FVC) in mL; timeFrame: 24 weeks; measure: Annual rate of decline in FVC in mL; timeFrame: 24 weeks; measure: Annual rate of decline in FVC in percent predicted; timeFrame: 24 weeks; measure: Change in HRCT fibrosis score; timeFrame: Baseline to Week 24

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history